NERATINIB (HKI-272), AN IRREVERSIBLE PAN ERBB RECEPTOR TYROSINE KINASE INHIBITOR: PHASE 2 RESULTS IN PATIENTS WITH ERBB2+ADVANCED BREAST CANCER

被引：0
|
作者：
Paridaens, R. [1 ]
Badwe, R. [2 ]
Sun, Y. [3 ]
Dirix, L. [4 ]
Cardoso, F. [5 ]
Powell, C. [6 ]
Zacharchuk, C. [7 ]
Burstein, H. J. [8 ]
机构：
[1] Univ Hosp Gasthuisberg Katholieke, Leuven, Belgium
[2] Tata Mem Hosp, Dept Surg Oncol, Mumbai 400012, Maharashtra, India
[3] Chinese Acad Med Sci, Beijing 100037, Peoples R China
[4] AZ St Augustinus, Oncol, Antwerp, Belgium
[5] Inst Jules Bordet, Med Oncol & Translat Res Unit, B-1000 Brussels, Belgium
[6] Wyeth Ayerst Res, Biostat, Cambridge, MA USA
[7] Wyeth Ayerst Res, Oncol, Cambridge, MA USA
[8] Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
ANNALS OF ONCOLOGY | 2009年 / 20卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：61 / 61
页数：1
相关论文
共 50 条
  • [1] Neratinib (HKI-272), an irreversible pan erbB receptor tyrosine kinase inhibitor: phase 2 results in patients with advanced HER2+breast cancer
    Burstein, H. J.
    Sun, Y.
    Tan, A. R.
    Dirix, L.
    Vermette, J. J.
    Powell, C.
    Zacharchuk, C.
    Badwe, R. A.
    CANCER RESEARCH, 2009, 69 (02) : 72S - 73S
  • [2] HKI-272, an irreversible pan erbB receptor tyrosine kinase inhibitor: preliminary phase 2 results in patients with advanced breast cancer.
    Burstein, H.
    Awada, A.
    Badwe, R.
    Dirix, L.
    Tan, A.
    Jacod, S.
    Lustgarten, S.
    Vermette, J.
    Zacharchuk, C.
    BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S268 - S268
  • [3] A Phase I Study with Neratinib (HKI-272), an Irreversible Pan ErbB Receptor Tyrosine Kinase Inhibitor, in Patients with Solid Tumors
    Wong, Kwok-K.
    Fracasso, Paula M.
    Bukowski, Ronald M.
    Lynch, Thomas J.
    Munster, Pamela N.
    Shapiro, Geoffrey I.
    Jaenne, Pasi A.
    Eder, Joseph P.
    Naughton, Michael J.
    Ellis, Matthew J.
    Jones, Suzanne F.
    Mekhail, Tarek
    Zacharchuk, Charles
    Vermette, Jennifer
    Abbas, Richat
    Quinn, Susan
    Powell, Christine
    Burris, Howard A.
    CLINICAL CANCER RESEARCH, 2009, 15 (07) : 2552 - 2558
  • [4] Neratinib (HKI-272), an irreversible pan-ErbB receptor tyrosine kinase inhibitor: preliminary results of a phase 2 trial in patients with advanced non-small cell lung cancer
    Besse, B.
    Eaton, K. D.
    Soria, J. C.
    Lynch, T. J.
    Miller, V.
    Wong, K. K.
    Powell, C.
    Quinn, S.
    Zacharchuk, C.
    Sequist, L. V.
    EJC SUPPLEMENTS, 2008, 6 (12): : 64 - 64
  • [5] HKI-272, an irreversible pan erbB receptor tyrosine kinase inhibitor: Preliminary phase 1 results in patients with solid tumors.
    Wong, K. K.
    Fracasso, P. M.
    Bukowski, R. M.
    Munster, P. N.
    Lynch, T.
    Abbas, R.
    Quinn, S. E.
    Zacharchuk, C.
    Burris, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 125S - 125S
  • [6] Neratinib, an Irreversible ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced ErbB2-Positive Breast Cancer
    Burstein, Harold J.
    Sun, Yan
    Dirix, Luc Y.
    Jiang, Zefei
    Paridaens, Robert
    Tan, Antoinette R.
    Awada, Ahmad
    Ranade, Anantbhushan
    Jiao, Shunchang
    Schwartz, Gary
    Abbas, Richat
    Powell, Christine
    Turnbull, Kathleen
    Vermette, Jennifer
    Zacharchuk, Charles
    Badwe, Rajendra
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (08) : 1301 - 1307
  • [7] Safety and Efficacy of Neratinib (HKI-272) in Combination with Paclitaxel in ErbB2+Metastatic Breast Cancer
    Chow, L.
    Gupta, S.
    Hershman, D.
    Jiang, Z.
    Epstein, R.
    Bondarenko, I
    Coughlin, C.
    Freyman, A.
    Zhao, Y.
    Abbas, R.
    Awada, A.
    CANCER RESEARCH, 2009, 69 (24) : 792S - 792S
  • [8] Safety and Efficacy of Neratinib (HKI-272) in Combination with Vinorelbine in ErbB2+Metastatic Breast Cancer
    Awada, A.
    Dirix, L.
    Beck, J.
    Luu, T.
    Dieras, V
    Llombart, A.
    Manso, L.
    Limentani, S.
    Binlich, F.
    Germa, C.
    Abbas, R.
    Agrapart, V
    Powell, C.
    Hershman, D.
    CANCER RESEARCH, 2009, 69 (24) : 797S - 797S
  • [9] SAFETY AND EFFICACY OF NERATINIB (HKI-272) IN COMBINATION WITH PACLITAXEL IN ERBB2+METASTATIC BREAST CANCER (MBC)
    Chow, L.
    Gupta, S.
    Hershman, D. L.
    Jiang, Z.
    Bondarenko, I.
    Coughlin, C.
    Freyman, A.
    Zhao, Y.
    Abbas, R.
    Piccart, M.
    ANNALS OF ONCOLOGY, 2010, 21 : 62 - 62
  • [10] SAFETY AND EFFICACY OF NERATINIB (HKI-272) IN COMBINATION WITH VINORELBINE IN ERBB2+METASTATIC BREAST CANCER (MBC)
    Awada, A.
    Dirix, L.
    Beck, J.
    Luu, T.
    Dieras, V.
    Manso, L.
    Binlich, F.
    Agrapart, V.
    Powell, C.
    Hershman, D. L.
    ANNALS OF ONCOLOGY, 2010, 21 : 62 - 63
12345